A randomized trial of omega-3 fatty acids plus inositol versus N-acetylcysteine for the treatment of depression and mania in emotionally dysregulated youth age 5-17 with and without autism traits.

J Affect DisordJul 16, 2026 (epub)
Clinical ResearchPsychiatryPediatrics

Janet Wozniak, Maria Iorini, Maura DiSalvo et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the effectiveness of omega-3 fatty acids plus inositol (O3I) versus N-acetylcysteine (NAC) in treating depression and mania in youth aged 5-17 with emotional dysregulation, including those with autism traits. Both treatments showed modest improvements, with O3I linked to significant within-group improvement in depression, while NAC showed trends towards greater effectiveness for mania.

Key findings

  • O3I showed significant within-group improvement in depression as measured by the Children's Depression Inventory.
  • NAC resulted in a greater decrease in Parent-Youth Mania Rating Scale scores compared to O3I, though not statistically significant.
  • In youth with autism traits, NAC was more effective for mania but not for depression.

Why it matters

Understanding the comparative effectiveness of nutraceutical treatments for emotional dysregulation in youth can guide clinicians in selecting appropriate interventions, particularly in populations with co-occurring autism traits.

Source

PubMed · PMID 42462928

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.